EIDD-2801 是核糖核苷类似物 EIDD-1931 的口服生物可利用的异丙酯前药。EIDD-2801 显示出广泛的抗流感病毒 (influenza virus) 和冠状病毒 (coronaviruses) 的活性，如?SARS-CoV-2，MERS-CoV，SARS-CoV。EIDD-2801 有用于 COVID-19 和季节性，流行性流感的潜力。
货号:ajcx11522
CAS:2349386-89-4
分子式:C??H??N?O?
分子量：329.31
溶解度:100 mg/mL in DMSO
纯度：98%
存储：Store at -20°C
库存：现货

Background:

EIDD-2801 is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. EIDD-2801 has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. EIDD-2801 has the potential for COVID-19, and seasonal and pandemic influenza treatment.

参考文献：
[1]. Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883.
[2]. Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11(515). pii: eaax5866.

Protocol:

EIDD-2801 (50-500 mg/kg; p.o.; every 12 hours for 3 days) is robustly antiviral and able to prevent SARS-CoV replication and disease^[1].
EIDD-2801 (7 mg/kg; p.o.; twice daily for 3.5 days) significantly reduces shed virus load and duration of fever^[2].

Animal Model:	C57BL/6 mice (intranasal infection with SARS-CoV)[1]
Dosage:	50, 150, 500 mg/kg
Administration:	Oral; every 12 hours for 3 days
Result:	Body weight loss is significantly diminished or prevented.

Animal Model:	Ca/09-infected female ferrets[1]
Dosage:	7 mg/kg
Administration:	Oral; twice daily for 3.5 days
Result:	Shed virus load and duration of fever were significantly reduced.